Original Research

DOI: 10.4244/EIJ-D-23-01068

Cardiac fibrosis as a predictor for sudden cardiac death after transcatheter aortic valve implantation

Fouzi Alnour1,2, MD; Bo E. Beuthner1,2, MD; Samy Hakroush3, MD; Rodi Topci1,2, MD; Anja Vogelgesang1,2, MD; Torben Lange1,2, MD; Tim Seidler1,2, MD; Ingo Kutschka4, MD; Karl Toischer1,2, MD; Andreas Schuster1,2, MD, PhD; Claudius Jacobshagen1,2,5, MD; Andreas Leha6, MD; Markus Zabel1,2, MD; Gerd Hasenfuß1,2, MD; Miriam Puls1,2, MD; Elisabeth M. Zeisberg1,2, MD

Abstract

BACKGROUND: Cardiac fibrosis plays a major pathophysiological role in any form of chronic heart disease, and high levels are associated with poor outcome. Diffuse and focal cardiac fibrosis are different subtypes, which have different pathomechanisms and prognostic implications. The total fibrosis burden in endomyocardial biopsy tissue was recently proved to play an independent prognostic role in aortic stenosis patients after transcatheter aortic valve implantation (TAVI).

AIMS: Here, for the first time, we aim to assess the specific impact of different fibrosis subtypes on sudden cardiac death (SCD) as a primary reason for cardiovascular mortality after TAVI.

METHODS: The fibrosis pattern was assessed histologically in the left ventricular biopsies obtained during TAVI interventions in 161 patients, who received a structured follow-up thereafter.

RESULTS: Receiver operating characteristic analyses, performed 6, 12, 24 and 48 months after TAVI, showed diffuse, but not focal, fibrosis as a significant predictor for SCD at all timepoints, with the highest area under the curve at the first time point and a decrease in its SCD predictivity over time. In both multivariate Cox proportional hazards and...

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 20 Number 12
Jun 17, 2024
Volume 20 Number 12
View full issue


Key metrics

On the same subject

10.4244/EIJV15I16A252 Mar 20, 2020
Myocardial fibrosis in severe aortic stenosis: how and when should we measure it?
Delgado V et al
free

Clinical research

10.4244/EIJ-D-19-00641 Mar 20, 2020
Outcomes of myocardial fibrosis in patients undergoing transcatheter aortic valve replacement
Sugiura A et al
free

Clinical research

10.4244/EIJ-D-22-00817 Jun 19, 2023
Impact of early changes in cardiac damage following transcatheter aortic valve implantation
Zhou Y et al
free

Clinical research

10.4244/EIJ-D-23-00590 Dec 4, 2023
Prognostic impact of cardiac damage staging classification in each aortic stenosis subtype undergoing TAVI
Nakase M et al

CLINICAL RESEARCH

10.4244/EIJY15M02_02 Apr 20, 2016
The prognostic value of acute and chronic troponin elevation after transcatheter aortic valve implantation
Sinning J et al
free
Trending articles
212.15

State-of-the-Art Review

10.4244/EIJ-D-21-01034 Jun 3, 2022
Management of in-stent restenosis
Alfonso F et al
free
173.13

Focus article

10.4244/EIJY19M08_01 Jan 17, 2020
EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update
Glikson M et al
free
168

Translational research

10.4244/EIJ-D-21-00824 May 15, 2022
Bench test and in vivo evaluation of longitudinal stent deformation during proximal optimisation
Toth GG et al
free
76.9

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved